Here's Won't Touch Teva: Why I Pass on the Generic Giant
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Want to get fast cash today? Discover various strategies that can help you secure money quickly and efficiently.
23,370 articlesTeva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
A focused look at the BOSC 2026 earnings transcript for Q1. This article breaks down revenue trends, margin health, a...
Oil States International (OIS) faces a shifting offshore market as 2025 unfolds. This guide breaks down the likely dr...
CoreWeave's stock has fallen sharply in May as costs rise and guidance disappoints. This guide breaks down the reason...
A growing cohort of dentists is turning to cash-balance plans to fund retirement beyond 401(k) limits, giving practic...
Fortinet reports a record free cash flow of $2.21 billion for 2025, yet the stock sits lower for the year. The gap un...
CrossCountry Mortgage plans a pro rata quarterly dividend for Two Harbors shareholders in the deal closing quarter, a...
Berkshire Hathaway’s cash pile nears the $400 billion mark, renewing scrutiny on what the conglomerate will do with v...
As biotech investors digest Recursion's latest quarterly results, this Deep Dive breaks down what recursion (rxrx) 20...
A detailed look at Seer’s Q1 2026 earnings, the forces shaping growth, and practical moves investors can make now. Le...
Strategy disrupted the market by using Bitcoin as a cash engine. The recent $216 million sale to fund dividends promp...
What could drive Entravision's 2025 earnings, and what should investors watch next? This guide breaks down the driver...